Humana says drugmakers can't avoid US antitrust claims over generic pricing
( May 21, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Humana opposed motions for summary judgment filed by Novartis, Sandoz, and other generic drugmakers over the pricing of various drugs. “There is overwhelming evidence (both direct and circumstantial) in the record to support Humana’s overarching conspiracy allegations. Witnesses have testified regarding a shared understanding in the industry referred to as the ‘rules of engagement’—often exemplified by other terms such as ‘playing nice in the sandbox’ or acting as a ‘responsible’ or ‘rational' competitor,” Humana argued.See attached files....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.